At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 106 enrolled
Drug / intervention
Fingolimod +1 moredrug
Likely dose
Fingolimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
In Brief
A Phase 3 clinical trial evaluating Fingolimod and Placebo Comparator for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed, enrolled 106 participants across 67 sites in 15 countries.
Detailed Summary
The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, Czechia, France, Germany, Greece, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom, United States
CollaboratorsTanabe Pharma Corporation
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartDec 2012
Primary CompletionSep 2016
TodayJul 2026
First PostedJun 21, 2012
Enrollment StartDec 22, 2012
Primary CompletionSep 3, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.0 years ago
Interventions
Fingolimoddrug
Fingolimod 0.5 mg capsules
Placebo Comparatordrug
Matching placebo capsules